| pubmed-article:15649387 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15649387 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:15649387 | lifeskim:mentions | umls-concept:C0025663 | lld:lifeskim |
| pubmed-article:15649387 | lifeskim:mentions | umls-concept:C0032105 | lld:lifeskim |
| pubmed-article:15649387 | lifeskim:mentions | umls-concept:C0680730 | lld:lifeskim |
| pubmed-article:15649387 | lifeskim:mentions | umls-concept:C0054173 | lld:lifeskim |
| pubmed-article:15649387 | lifeskim:mentions | umls-concept:C0599748 | lld:lifeskim |
| pubmed-article:15649387 | lifeskim:mentions | umls-concept:C1519941 | lld:lifeskim |
| pubmed-article:15649387 | lifeskim:mentions | umls-concept:C1148554 | lld:lifeskim |
| pubmed-article:15649387 | lifeskim:mentions | umls-concept:C0008565 | lld:lifeskim |
| pubmed-article:15649387 | lifeskim:mentions | umls-concept:C1708476 | lld:lifeskim |
| pubmed-article:15649387 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:15649387 | pubmed:dateCreated | 2005-1-14 | lld:pubmed |
| pubmed-article:15649387 | pubmed:abstractText | A new sensitive and specific method using liquid chromatography/tandem mass spectrometry for determination of bryostatin 1 was developed and validated. Sample pretreatment involved a double liquid-liquid extraction step with a mixture of acetonitrile/n-butyl chloride (1/4, v/v). Separation of the compound of interest, including the internal standard paclitaxel, was achieved on a Waters X-Terra C18 (50 x 2.1 mm i.d., 3.5 microm) analytical column with acetonitrile/water mobile phase (80:20, v/v) containing 0.1% formic acid using isocratic flow at 0.15 mL/min for 13 min. The analytes of interest were monitored by tandem mass spectrometry with electrospray positive ionization. The linear calibration curves were generated over the range of 50-2000 pg/mL with values for the coefficient of determination of >0.99. The values for both within-day and between-day precision and accuracy were <15%. This method was used to characterize the plasma pharmacokinetics of bryostatin 1 at doses of 20 microg/m2) to optimize treatment with this agent. | lld:pubmed |
| pubmed-article:15649387 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15649387 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15649387 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15649387 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15649387 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15649387 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15649387 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15649387 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15649387 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:15649387 | pubmed:issn | 0003-2697 | lld:pubmed |
| pubmed-article:15649387 | pubmed:author | pubmed-author:BakerSharyn... | lld:pubmed |
| pubmed-article:15649387 | pubmed:author | pubmed-author:RudekMichelle... | lld:pubmed |
| pubmed-article:15649387 | pubmed:author | pubmed-author:ZhaoMingM | lld:pubmed |
| pubmed-article:15649387 | pubmed:author | pubmed-author:HePingP | lld:pubmed |
| pubmed-article:15649387 | pubmed:author | pubmed-author:SmithB... | lld:pubmed |
| pubmed-article:15649387 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15649387 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:15649387 | pubmed:volume | 337 | lld:pubmed |
| pubmed-article:15649387 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15649387 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15649387 | pubmed:pagination | 143-8 | lld:pubmed |
| pubmed-article:15649387 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:15649387 | pubmed:meshHeading | pubmed-meshheading:15649387... | lld:pubmed |
| pubmed-article:15649387 | pubmed:meshHeading | pubmed-meshheading:15649387... | lld:pubmed |
| pubmed-article:15649387 | pubmed:meshHeading | pubmed-meshheading:15649387... | lld:pubmed |
| pubmed-article:15649387 | pubmed:meshHeading | pubmed-meshheading:15649387... | lld:pubmed |
| pubmed-article:15649387 | pubmed:meshHeading | pubmed-meshheading:15649387... | lld:pubmed |
| pubmed-article:15649387 | pubmed:meshHeading | pubmed-meshheading:15649387... | lld:pubmed |
| pubmed-article:15649387 | pubmed:meshHeading | pubmed-meshheading:15649387... | lld:pubmed |
| pubmed-article:15649387 | pubmed:meshHeading | pubmed-meshheading:15649387... | lld:pubmed |
| pubmed-article:15649387 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15649387 | pubmed:articleTitle | Validation and implementation of a method for determination of bryostatin 1 in human plasma by using liquid chromatography/tandem mass spectrometry. | lld:pubmed |
| pubmed-article:15649387 | pubmed:affiliation | The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA. | lld:pubmed |
| pubmed-article:15649387 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15649387 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:15649387 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| pubmed-article:15649387 | pubmed:publicationType | Validation Studies | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15649387 | lld:pubmed |
